BeiGene Ltd. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 45 Posts
1 2 3
Week In Review: CICC Capital Closes $229 Million China Fund For Biologics
Article By: ChinaBio® Today Saturday, February 29, 2020 1:50 PM EDT
CICC Capital closed a $229 million investment fund for biologics, with investments coming mainly from Chinese organizations inside and outside the biopharma industry. Some of the money will go to companies making COVID-19 vaccines and therapies.
In this article: AZN, GSK, PFE, GILD, MRNA, BGNE, VIR
Read
Week In Review: Shanghai's I-Mab Plans $100 Million NASDAQ IPO On January 16
Article By: ChinaBio® Today Sunday, January 5, 2020 10:20 AM EDT
I-Mab, a Phase III Shanghai immunoncology-autoimmune biopharma, announced the terms for its $100 million IPO on the NASDAQ exchange at a market value of $750 million. The company plans to offer 7.4 million shares between $12 and $15.
In this article: BGNE, LPTX
Read
Week In Review: Ally Bridge Leads $140 Million Of Investments In Three Medical Device Companies
Article By: ChinaBio® Today Saturday, December 21, 2019 5:09 PM EDT
Ally Bridge Group, a Hong Kong-New York life science investment firm, announced it has led $140 million of investments in three new medical device companies, bringing its 18-month total to more than $500 million in private life science companies.
In this article: BGNE, TCON
Read
Week In Review: AlphaMab Raises $234 Million In Hong Kong IPO; Climbs 35% In First Trading Session
Article By: ChinaBio® Today Saturday, December 14, 2019 5:09 PM EDT
Alphamab Oncology raised $234 million in a Hong Kong IPO and traded 35% higher from its offering price to a market cap of $1.2 billion. The company has a PD-L1 candidate that could be approved in China in 2020 and two bispecifics in Phase II tests.
In this article: AZN, BGNE
Read
Week In Review: BeiGene's BTK Inhibitor Approved In US And China Approval For PD-1 Expected In Two Months
Article By: ChinaBio® Today Saturday, November 16, 2019 4:09 PM EDT
Beijing's BeiGene had an outstanding week: its BTK drug, Brukinsa™, was approved for US use to treat mantle cell lymphoma, and its PD-1 candidate is poised for China approval before the end of the year to treat classical Hodgkin’s lymphoma.
In this article: HCM, BGNE, ASLN
Read
Week In Review: AstraZeneca Announces $1 Billion Fund For China Life Science Startups
Article By: ChinaBio® Today Saturday, November 9, 2019 6:15 PM EDT
Deals, financings, trials and approvals in China biotech this past week.
In this article: AZN, SCR, CICC, BGNE
Read
Week In Review: BeiGene Forms Blockbuster $2.7 Billion Collaboration With Amgen
Article By: ChinaBio® Today Sunday, November 3, 2019 1:34 AM EDT
BeiGene, a Beijing cancer biopharma, announced a blockbuster collaboration with Amgen. I-Mab, a Shanghai biopharma, has filed to IPO; Aesthetic Medical International Holdings, a Shenzhen aesthetics company, completed a $30 million IPO on NASDAQ.
In this article: LLY, AMGN, BGNE, AIH, SNCA
Read
The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance
Article By: Benzinga Friday, November 1, 2019 7:38 AM EDT
Here's a roundup of top developments in the biotech space over the last 24 hours.
In this article: AMGN, BGNE, MNK, PRTK, IDYA, CDNA, BLUE Also: HOTH, AGN, AZN, BMY, GSK, RMD, ACOR, ACRX, ALIM, AMAG, BCRX, CERS, IMGN, NURO, RMTI, CELG, VRTX, ABBV, AGIO, REPH, RETA, PRTO, MGNX, OPGN, MGEN, DOVA, DRNA, DCPH, TRVI, OYST, RAPT, ARDS, MIRM, ITRM, COCP, CYCN, GMAB
Read
Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months
Article By: T.J. Hayes Monday, September 9, 2019 7:36 PM EDT
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.
In this article: ALNY, ALXN, BMRN, CBPO, ILMN, INCY, JAZZ, REGN, SGEN, AMGN, BIIB, CELG, EXEL, GILD, HZNP, MYL, NBIX, TECH, VRTX, AMRN, SAGE, GWPH, SRPT, BLUE, NVCR, IONS, BGNE, PRAH, SYNH, IBB
Read
Week In Review: SinoMab To IPO On Hong Kong Exchange
Article By: ChinaBio® Today Saturday, July 13, 2019 7:25 PM EDT
Hong Kong's SinoMab published its prospectus for a Hong Kong IPO to support its antibody program for autoimmune and oncology mAbs.
In this article: NVS, GSX, GILD, BGNE
Read
Week In Review: Hansoh Plans Hong Kong IPO To Raise Up To $1 Billion
Article By: ChinaBio® Today Saturday, April 13, 2019 4:09 PM EDT
Hansoh Pharma, an established drug company, has filed for a Hong Kong IPO, and is rumored to seek between $500 million and $1 billion in new capital. It's a profitable drug company with $1.1 billion in revenue and more than $280 million in profits.
In this article: ROG, BGNE, BAYN, BAYN
Read
Week In Review: Grifols Pays $1.9 Billion For 26% Stake In Shanghai RAAS
Article By: ChinaBio® Today Saturday, March 9, 2019 4:13 PM EDT
Grifols, a Barcelona maker of plasma-based medicines, acquired a 26% stake in Chinese blood plasma company Shanghai RAASfor $1.9 billion in a non-cash deal. Grifols will exchange a 45% ownership in Grifols Diagnostic Solutions for the RAAS stake.
In this article: CASI, BGNE, GRFS, NVO
Read
Week In Review: Yantai's MabPlex Raises $59 Million To Expand CDMO Services
Article By: ChinaBio® Today Sunday, January 20, 2019 10:38 AM EDT
MabPlex, a biologics CDMO, raised $59 million in a Series A round from SDIC Venture Fund and Shenzhen Venture Capital. MabPlex offers biologics development and manufacturing services, including mAbs, recombinant proteins, ADCs and bispecifics.
In this article: AZN, IRWD, CBMG, BGNE
Read
Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks
Article By: ChinaBio® Today Saturday, December 1, 2018 4:44 PM EDT
BeiGene of Beijing announced cancer drug deals worth up to $1.3 billion with Vancouver's Zymeworks. BeiGene will acquire Asian rights to two bispecific antibodies from Zymeworks and will have rights to three to-be-discovered bispecific candidates.
In this article: LLY, HCM, BGNE, MGNX, ZLAB, TCON, ZYME, BHVN
Read
Week In Review: Biosense Exercises $75 Million Option For China Rights To Neovacs' Lupus Immunotherapy
Article By: ChinaBio® Today Saturday, October 13, 2018 4:59 PM EDT
Biosense Global, a New Jersey-Suzhou in-licensing company, exercised a $75 million option for China rights to an active lupus immunotherapy developed by Neovacs, following a successful Phase II trial of the therapeutic vaccine, IFNalpha Kinoid.
In this article: MEIP, BGNE
Read
Week In Review: Jiangsu Hansoh To Raise Up To $3 Billion In Hong Kong IPO
Article By: ChinaBio® Today Saturday, September 8, 2018 4:22 PM EDT
Hansoh, a China pharma based in Lianyungang, Jiangsu province, has applied to stage an IPO on the Hong Kong exchange. Unlike most companies seeking Hong Kong IPOs, Hansoh is both profitable and established.
In this article: GSK, LLY, BGNE, ZLAB, ROG, HCM, MRK
Read
1 to 16 of 45 Posts
1 2 3